Histone Deacetylase Inhibitors Market Trends

Growth Drivers

• Rising Incidence of Neurodegenerative Disorders – In addition to improving neurological function, HDAC inhibitors also have anti-inflammatory, neurotrophic, and neuroprotective properties as a result it has drawn a lot of attention for Huntington's disease, which is a polyglutamine illness, and other neurological disorders. For instance, more than 10% of the global population today suffers from neurological illnesses, which are the most common cause of physical and cognitive disability.
• Spiking Cases of Multiple Myeloma- For the treatment of multiple myeloma, HDAC inhibitors have received clinical approval as they have demonstrated potential efficacy in the treatment of relapsed multiple myeloma.
• Growing Popularity of Target Therapies- Histone deacetylase inhibitors are novel targeted therapies that can target the expression of HDACs, which makes them attractive therapeutic targets.
• Increase in Number of People with Cachexia- In advanced stages of many chronic diseases, such as chronic heart failure, cachexia frequently appears and HDAC inhibitor is one way to treat cachexia in cancer-bearing mammals.
• Development of Combination Therapies-  HDACi have shown promising anticancer effects when combined with conventional chemotherapeutic medicines since by increasing histone acetylation and gene expression, the susceptibility of cancer cells to chemotherapy increases.
• Urothelial Carcinoma Therapy- Promising anti-cancer medications known as histone deacetylase inhibitors (HDACi) may also be used for urothelial carcinoma treatment as it enhances expression of the transgene.
• Increasing Prevalence of Rare Diseases- HDAC inhibitors (HDACi), have demonstrated promise in the treatment of several rare illnesses such as (RTT) Rett Syndrome an uncommon neurodevelopmental disease that is mostly attributed to the lack of functional mutations.

Challenges

• Adverse Effects of HDAC (Histone Deacetylase) Inhibitors - Some side effects of the inhibitors (grades III and IV) include a variety of serious and/or severe side effects that are agent- and class-specific, including myelosuppression, diarrhea, as well as the most concerning side effect, which includes ventricular arrhythmia, has been cardiac toxicity all of which are recoverable with drug withdrawal.
• Limited Reimbursement Policies in Developing Regions
• High Cost of Research & Development Activities